Navigation Links
Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
Date:12/10/2011

ffect. Recognizing this challenge, researchers sought to create a new method to suppress GVHD without compromising the GVT effect by using genetically engineered donor T-cells that over-express a protein known to induce cell death in an effort to specifically attack cancer cells.

The protein, Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand, or TRAIL, is naturally expressed on some immune cells in the body. TRAIL targets tumor cells and keeps them from multiplying and spreading by interacting with death receptor molecules, which are highly expressed on the surface of tumor cells, making them more susceptible to therapeutic targeting using TRAIL.

To evaluate the effect of genetically engineered donor T-cells over-expressing TRAIL (TRAIL+) on GVHD and GVT, investigators from Memorial Sloan-Kettering Cancer Center performed HCT using TRAIL+ donor T-cells versus control donor T-cells in experimental mouse models with cancerous tumors. Mice that received TRAIL+ donor T-cells displayed significantly higher survival rates, indicating greater antitumor activity than in those treated with control donor T-cells. The researchers also used donor TRAIL+ progenitor T-cell with autologous (stem cells from the patient) HCT in tumor-bearing mice and found a significantly higher anti-tumor effect compared with controls. In addition to enhanced GVT effect, the transplant recipients treated with TRAIL+ T-cells experienced significantly less severe GVHD. Researchers further found that the immune cells, which trigger GVHD, also express TRAIL-sensitive death receptors, and TRAIL+ T-cells can suppress GVHD by targeting these cells.

"Our data show that donor T-cells over-expressing TRAIL can suppress GVHD while simultaneously enhancing the GVT effects. We hope this approach will provide fresh insights into separating cancer cell killing from indiscriminate killing of normal tissues," said Arnab Ghosh, MD, PhD, lead author and a Research Scholar in the lab
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
2. Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
3. Montage Announces Three More Hospitals Implement Their On-Demand Search and Data Mining Technology for Radiology Studies
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
6. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
7. New Clinical Studies Presented at the American Society of Anesthesiologists Annual Meeting Show Benefits of Masimo Noninvasive Technologies: SpHb, PVI, RRa, and SEDLine
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Managing Bioequivalence Studies to Optimize the Quality, Cost, and Speed of Generics Manufacturing
10. FDA Seeks Comment on Proposed Guidelines for High-Quality Clinical Studies
11. Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... LEIDEN, The Netherlands, July 6 Three ... Therapeutics and InteRNA,Technologies - have joined public-private partnership TI ... on cancer and,inflammatory diseases, have a total budget of ... The new consortium, formed by Syncom, Synvolux Therapeutics, and,University ...
... , NEW YORK, June 30 Betsy McCaughey of the Committee ... hospital infection rates made available by the NYS Department of Health ... have the lowest infection rates - and steer clear of those ... , Betsy McCaughey, a Ph.D., founded RID in 2004 with a ...
Cached Medicine Technology:New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:9/30/2014)... Keystone Symposia will convene the first conference of ... Global Health Series on "The Modes of Action ... immediately following the conclusion of the Grand Challenges Meeting ... of the Keystone Symposia Global Health Series, supported by ... funded travel awards for 36 investigators from developing countries ...
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... Calif., Sept. 30, 2014 Research by UC Irvine ... functions, shedding light on a vital process that determines ... In the online version of Nature Immunology , ... and other Institute for Immunology colleagues describe a critical ... released into the bloodstream. , A T cell is ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... by Blue Star Nutraceuticals designed to help maximize lean, ... that optimizes the body’s absorption of glucose has caught ... , “The main purpose behind Glycodrive is to ... builds lean muscle,” reports Michaels. “Carbs are essential in ...
(Date:9/30/2014)... 30, 2014 Elevate , the latest ... better in and out of the gym by providing natural ... the attention of Shane Michaels, prompting an investigative review. ... the reason most people simply just don’t have the ability ... focused at work, getting the motivation to finish a project, ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UCI study uncovers important process for immune system development 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2
... Authorizations and Reduces DenialsGREENWOOD VILLAGE, Colo., March 25 ... cycle solutions for the healthcare industry, today announced ... and denial prevention product for hospitals. Missing authorizations ... 15 percent of all payer-denied claims, and can ...
... Inc., the largest privately held spinal implant manufacturer ... MicroFuse(TM) ST Granules, a unique resorbable polymer bone ... MicroFuse(TM) technology utilizes proprietary combinations of poly (lactic ... patented microsphere process to deliver up to twelve ...
... 50 raises odds almost 4-fold , , WEDNESDAY, March 25 (HealthDay ... fourfold increased risk of melanoma in women under the age ... York University School of Medicine. , Identification of this variation ... test to identify women at high risk for the deadly ...
... ACell, Inc. and its founder, Alan Spievack, MD, ... Spievack described how his severed finger grew back after ... technology is a naturally occurring bioscaffold derived from porcine ... it is resorbed and replaced with new native tissue ...
... Dr. Ching-Hua Wang, Chair of Biology, Geology and Nursing, ... California State University Channel Islands , was recently awarded ... Medicine (CIRM) as a part of their Bridges to Stem ... to receive funding from the program. , , ...
... "Today was a monumental day on Capitol Hill ... long-term services and supports.We commend the Senate Finance Committee ... in this year,s health care reform. Long-term services and ... America,s health care crisis. The needs are great. The ...
Cached Medicine News:Health News:Recondo Technology Announces Authorization and Denial Prevention Software Service 2Health News:Globus Medical's MicroFuse(TM) Technology Engineered for Optimal Strength and Porosity 2Health News:Gene Test May ID Younger Women at Risk for Melanoma 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 2Health News:CSUCI Receives $1.7 Million Grant for Stem Cell Research Program 3Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 2Health News:Statement From Larry Minnix, President & CEO of the American Association of Homes and Services for the Aging, on the Senate Finance Committee Hearing 'The Role of Long-term Care in Health Reform' and the Reintroduction of the CLASS Act 3
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and negative ... inoculation. With these slides, perform QC and ... enhance their education and training programs by ... interpretation, all on one slide! KWIK-QC slides ...
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population....
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: